CD86 occupancy in belatacept-treated kidney transplant patients is not associated with clinical and infectious outcomes
© 2022 The American Society of Transplantation and the American Society of Transplant Surgeons..
The CD86 occupancy assay has been developed to measure the number of CD86 molecules unbound to belatacept, but its association with clinical outcomes has not been assessed yet. All kidney transplant patients switched to belatacept in our center between 2016 and 2018 were included. Blood samples were collected before each infusion for 1 year to assess CD86 occupancy by CD86 antibody cytometry staining on the surface of CD14+ monocytes. Results were expressed as the median fluorescence intensity (MFI) value of CD86 staining. At each infusion, the MFIDay of infusion /MFIDay 0 ratio was calculated. Forty-one patients were consecutively included. After every 2-week infusion period, CD86 MFI ratio dropped from 1.00 to 0.73 [0.57-0.98], p = .07. However, this ratio progressively increased to 0.78 [0.53-1.13] at 1 year, which was not statistically different from pre-switch ratio, p = .4. Over the first year, the MFI ratio coefficient of variation was 31.58% [23.75-38.31]. MFI ratio was not different between patients with or without opportunistic infections: 0.73 [0.60-0.88] versus 0.80 [0.71-1.00], p = .2, or between patients with or without EBV DNAemia, p = .2. Despite previous in vitro results, the CD86 occupancy assay suffers from a high intra-individual variability and does not appear to be relevant to clinical outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons - 22(2022), 6 vom: 25. Juni, Seite 1691-1698 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Nattes, Tristan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7D0YB67S97 |
|---|
| Anmerkungen: |
Date Completed 09.06.2022 Date Revised 24.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ajt.17005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33713846X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33713846X | ||
| 003 | DE-627 | ||
| 005 | 20231225233728.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ajt.17005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM33713846X | ||
| 035 | |a (NLM)35181996 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Nattes, Tristan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CD86 occupancy in belatacept-treated kidney transplant patients is not associated with clinical and infectious outcomes |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.06.2022 | ||
| 500 | |a Date Revised 24.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The American Society of Transplantation and the American Society of Transplant Surgeons. | ||
| 520 | |a The CD86 occupancy assay has been developed to measure the number of CD86 molecules unbound to belatacept, but its association with clinical outcomes has not been assessed yet. All kidney transplant patients switched to belatacept in our center between 2016 and 2018 were included. Blood samples were collected before each infusion for 1 year to assess CD86 occupancy by CD86 antibody cytometry staining on the surface of CD14+ monocytes. Results were expressed as the median fluorescence intensity (MFI) value of CD86 staining. At each infusion, the MFIDay of infusion /MFIDay 0 ratio was calculated. Forty-one patients were consecutively included. After every 2-week infusion period, CD86 MFI ratio dropped from 1.00 to 0.73 [0.57-0.98], p = .07. However, this ratio progressively increased to 0.78 [0.53-1.13] at 1 year, which was not statistically different from pre-switch ratio, p = .4. Over the first year, the MFI ratio coefficient of variation was 31.58% [23.75-38.31]. MFI ratio was not different between patients with or without opportunistic infections: 0.73 [0.60-0.88] versus 0.80 [0.71-1.00], p = .2, or between patients with or without EBV DNAemia, p = .2. Despite previous in vitro results, the CD86 occupancy assay suffers from a high intra-individual variability and does not appear to be relevant to clinical outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD86 | |
| 650 | 4 | |a belatacept | |
| 650 | 4 | |a kidney transplant | |
| 650 | 4 | |a opportunistic infection | |
| 650 | 4 | |a therapeutic monitoring | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Abatacept |2 NLM | |
| 650 | 7 | |a 7D0YB67S97 |2 NLM | |
| 700 | 1 | |a Lebourg, Ludivine |e verfasserin |4 aut | |
| 700 | 1 | |a Etienne, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Laurent, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Lemoine, Mathilde |e verfasserin |4 aut | |
| 700 | 1 | |a Dumont, Audrey |e verfasserin |4 aut | |
| 700 | 1 | |a Guerrot, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Jacquot, Serge |e verfasserin |4 aut | |
| 700 | 1 | |a Candon, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Bertrand, Dominique |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons |d 2001 |g 22(2022), 6 vom: 25. Juni, Seite 1691-1698 |w (DE-627)NLM119667924 |x 1600-6143 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:6 |g day:25 |g month:06 |g pages:1691-1698 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ajt.17005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 6 |b 25 |c 06 |h 1691-1698 | ||